Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?

Theo M. De Witte, David Bowen, Marie Robin, Luca Malcovati, Ghulam Mufti, Dietger Niederwieser, Ibrahim Yakoubagha, Nicolaus Kröger

Research output: Contribution to journalArticle

Abstract

The selection of a treatment strategy before allogeneic hematopoietic stem cell transplant (HSCT) for myelodysplastic syndrome is a delicate process. The expected relapse risk and nonrelapse mortality after HSCT and the response rates to the pretransplant strategies all play a role in this process. Fit patients younger than 60 to 65 years with > 10% marrow blasts and without high-risk cytogenetic abnormalities should be seriously considered for intensive chemotherapy (ICT) to reduce tumor load before HSCT. Other patients up to the age of 75 years may be considered for hypomethylating agent therapy before transplant. Patients with high-risk cytogenetic abnormalities should be treated in investigational protocols if they are not candidates for ICT.

Original languageEnglish
Pages (from-to)S42-S45
JournalClinical Lymphoma, Myeloma and Leukemia
Volume14
DOIs
Publication statusPublished - Sep 1 2014

Fingerprint

Remission Induction
Induction Chemotherapy
Myelodysplastic Syndromes
Hematopoietic Stem Cells
Transplants
Chromosome Aberrations
Drug Therapy
Therapeutics
Tumor Burden
Bone Marrow
Recurrence
Mortality

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Cytoreduction with hypomethylating agents
  • Cytoreduction with intensive chemotherapy
  • High-Risk myelodysplastic syndrome
  • Transformed myelodysplastic syndrome

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology
  • Medicine(all)

Cite this

Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy? / De Witte, Theo M.; Bowen, David; Robin, Marie; Malcovati, Luca; Mufti, Ghulam; Niederwieser, Dietger; Yakoubagha, Ibrahim; Kröger, Nicolaus.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, 01.09.2014, p. S42-S45.

Research output: Contribution to journalArticle

@article{b8098dfbdf674d538e5296f74241b611,
title = "Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?",
abstract = "The selection of a treatment strategy before allogeneic hematopoietic stem cell transplant (HSCT) for myelodysplastic syndrome is a delicate process. The expected relapse risk and nonrelapse mortality after HSCT and the response rates to the pretransplant strategies all play a role in this process. Fit patients younger than 60 to 65 years with > 10{\%} marrow blasts and without high-risk cytogenetic abnormalities should be seriously considered for intensive chemotherapy (ICT) to reduce tumor load before HSCT. Other patients up to the age of 75 years may be considered for hypomethylating agent therapy before transplant. Patients with high-risk cytogenetic abnormalities should be treated in investigational protocols if they are not candidates for ICT.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Cytoreduction with hypomethylating agents, Cytoreduction with intensive chemotherapy, High-Risk myelodysplastic syndrome, Transformed myelodysplastic syndrome",
author = "{De Witte}, {Theo M.} and David Bowen and Marie Robin and Luca Malcovati and Ghulam Mufti and Dietger Niederwieser and Ibrahim Yakoubagha and Nicolaus Kr{\"o}ger",
year = "2014",
month = "9",
day = "1",
doi = "10.1016/j.clml.2014.06.015",
language = "English",
volume = "14",
pages = "S42--S45",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?

AU - De Witte, Theo M.

AU - Bowen, David

AU - Robin, Marie

AU - Malcovati, Luca

AU - Mufti, Ghulam

AU - Niederwieser, Dietger

AU - Yakoubagha, Ibrahim

AU - Kröger, Nicolaus

PY - 2014/9/1

Y1 - 2014/9/1

N2 - The selection of a treatment strategy before allogeneic hematopoietic stem cell transplant (HSCT) for myelodysplastic syndrome is a delicate process. The expected relapse risk and nonrelapse mortality after HSCT and the response rates to the pretransplant strategies all play a role in this process. Fit patients younger than 60 to 65 years with > 10% marrow blasts and without high-risk cytogenetic abnormalities should be seriously considered for intensive chemotherapy (ICT) to reduce tumor load before HSCT. Other patients up to the age of 75 years may be considered for hypomethylating agent therapy before transplant. Patients with high-risk cytogenetic abnormalities should be treated in investigational protocols if they are not candidates for ICT.

AB - The selection of a treatment strategy before allogeneic hematopoietic stem cell transplant (HSCT) for myelodysplastic syndrome is a delicate process. The expected relapse risk and nonrelapse mortality after HSCT and the response rates to the pretransplant strategies all play a role in this process. Fit patients younger than 60 to 65 years with > 10% marrow blasts and without high-risk cytogenetic abnormalities should be seriously considered for intensive chemotherapy (ICT) to reduce tumor load before HSCT. Other patients up to the age of 75 years may be considered for hypomethylating agent therapy before transplant. Patients with high-risk cytogenetic abnormalities should be treated in investigational protocols if they are not candidates for ICT.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Cytoreduction with hypomethylating agents

KW - Cytoreduction with intensive chemotherapy

KW - High-Risk myelodysplastic syndrome

KW - Transformed myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84939455664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939455664&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2014.06.015

DO - 10.1016/j.clml.2014.06.015

M3 - Article

C2 - 25486954

AN - SCOPUS:84939455664

VL - 14

SP - S42-S45

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

ER -